WO1991008488A1 - Peptide (alpha, at) inhibiteur de trypsine, immunoanalyse, anticorps monoclonal et hybridome - Google Patents

Peptide (alpha, at) inhibiteur de trypsine, immunoanalyse, anticorps monoclonal et hybridome Download PDF

Info

Publication number
WO1991008488A1
WO1991008488A1 PCT/SE1990/000768 SE9000768W WO9108488A1 WO 1991008488 A1 WO1991008488 A1 WO 1991008488A1 SE 9000768 W SE9000768 W SE 9000768W WO 9108488 A1 WO9108488 A1 WO 9108488A1
Authority
WO
WIPO (PCT)
Prior art keywords
lys
antitrypsin
monoclonal antibodies
amino acid
thr
Prior art date
Application number
PCT/SE1990/000768
Other languages
English (en)
Inventor
Jan Olof Jeppsson
Original Assignee
Ferring Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Ab filed Critical Ferring Ab
Publication of WO1991008488A1 publication Critical patent/WO1991008488A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin

Definitions

  • the present invention relates to a decapeptide cor- responding to the amino acids 338-347 of Lys 342- ⁇ .-anti- trypsin (Z-protein), and the use of this decapeptide coupled to an inert carrier, in a method for obtaining a hybridoma cell line producing monoclonal antibodies speci- fically binding to only one epitope of Lys 342- ⁇ .-anti- trypsin comprising Lys 342.
  • the invention further encom- passes monoclonal antibodies specifically binding to said epitope and ,a hybridoma cell line producing said mono ⁇ clonal antibodies.
  • the invention is directed to a method for in vitro diagnosis of a. -antitrypsin defi ⁇ ciency in man, using said monoclonal antibodies, and an immunoassay kit for said diagnosis.
  • ⁇ .-glycoprotein was isolated and desig ⁇ nated a.-antitrypsin ( ⁇ .AT) after its ability to bind tryp ⁇ sin had been observed (Schultze, H.E., Heide, K., and Haupt, H., .-Antitrypsin aus Humanserum. Klin. ochenschr. 40, 427-429 (1962)).
  • ⁇ .-antitrypsin As the name . -antitrypsin indicates, it is the main component in the . -electrophoretic band of human plas aproteins and acts as an inhibitor of proteo- lytic enzymes. It is now known that ⁇ .-antitrypsin is one of the major extracellular serine protease inhibitors in man.
  • CC-AT is the most important extra ⁇ cellular protease inhibitor whose main function is to in ⁇ activate elastase liberated from leucocytes and macro- phages. Therefore, ⁇ .-antitrypsin has also been referred to as ⁇ .-protease inhibitor (cc.PI) which better indicates its function (Johnson, D.R., Pannell, R.N., and Travies, J. , The molecular stoichiometry of trypsin inhibition by human ⁇ .-proteinase inhibitor. Biochem. Biophys. Res. Commun. 57, 584-589 (1974)).
  • cc.PI ⁇ .-protease inhibitor
  • ⁇ ..-antitrypsin has a polypeptide chain of 394 amino acid residues, and three carbohydrate side chains, giving a molecular weight of 51 kDa (Carrel, R.W., Jeppsson, J-0 and Laurell C-B. Structure and variation of human .-antitryp ⁇ sin. Nature (1982) 298, 329).
  • oc.AT exhibits a considerable genetic variation with more than 60 variants (Jeppsson, J-0 and Franzen, B. Typing of Genetic variants of ⁇ .-antitryp- sin by Electrofocusing. Clin Chemistry (1982) 28, 219).
  • variants or, in other words, alleles are designated by letters according to their electrophoretic mobility, primarily in starch gel electrophoresis and later according to their appearance in isoelectric focusing.
  • Pi prote inhibitor
  • Fagerhol M.K. Ser. Haemat. 1 , Suppl. 1, 153-161 (1968).
  • the PI* M-allele is the most common and corresponds to a normal amount of c.AT in plasma. Of clinical interest are three alleles giving lower concentrations of ⁇ .AT in plasma.
  • Variants of particular interest are the common Z- and S-mutants giving low concentrations of ⁇ ---antitrypsin in plasma; the product of the Z-allele gives concentra- tions corresponding to 15% of the concentration of the normal M-allele, while the product of the S-allele gives concentrations of 60% of the normal allele.
  • Mixed hetero- zygotes, such as MZ, MS and SZ give proportionally chang ⁇ ed plasma levels.
  • the genotypes giving such a deficiency of ⁇ . -antitrypsin in plasma which is an evident health hazard, are PiZZ (15% of normal concentration), PiSZ (35% of normal concentration) and combinations with an uncommon 0 (-)gene, such as PiZ- (8% of normal concentration).
  • the difference in charge between M-, S- and Z-pro- teins depends on amin ⁇ acid substitutions. Glutamic acid in position 342 of the M-protein is replaced by lysine in the Z-protein, and glutamic acid in position 264 of the M-protein is replaced by valine in the S-protein.
  • Deficiency in, or rather low concentration of, the plasmaprotein .-antitrypsin is correlated with the pre ⁇ sence of lung emphysema (Eriksson, S. Acta Med. Scand. 175, 197-205 (1964)) and certain liver diseases (Sharp. H.L. Hosp. Pract. 6. 83-96 (1971)).
  • augmentation therapy with isolated human a.-antitrypsin might be offered to prevent chronic de ⁇ struction of the lung (Hubbard R.C. et al. Biochemical efficacy and safety of monthly augmentation therapy for ⁇ 1 -antitrypsin deficiency. JAMA (1988) 260, 1259).
  • Diagnosing .-antitrypsin deficiency has hitherto been done by quantitative determination of cc.-antitrypsin in plasma, supplemented with electrofocusing at low le ⁇ vels. This is a relatively laborious and complicated tech- nique. Therefore, there is a need for a simpler and faster technique allowing routine analysis of blood samples with an aim to locate at an early stage individuals having a.
  • Wallmark A. and co-workers produced an antibody against cc..-antitrypsin isolated from the liver of a PiZZ indivi ⁇ dual and used said antibody in ELISA for the detection of PiZ gene carriers (Wallmark A., et al. Monoclonal antibody specific for the mutant PiZ cc.-antitrypsin and its appli- cation in an ELISA procedure for identification of PiZ gene carriers. Proc.Natl.Acad.Sci. USA, Vol. 81, pp 5690-5693 (1984)).
  • the present invention is based on a decapeptide cor ⁇ responding to amino acids 338-347 in the amino acid se ⁇ quence of the Z-protein. With the aid of this decapeptide, it has been possible to produce monoclonal antibodies spe- cifically binding to only one epitope of Lys 342 - .-anti- trypsin comprising Lys 342. Said monoclonal antibodies have then been used in a method of in vitro diagnosis of a. - antitrypsin deficiency, that is the presence in the blood of Lys 342- ⁇ .-antitrypsin, in man, and distinguishing between a heterozygote and a homozygote PiZ gene carrier.
  • One aspect of the invention is directed to a decapep ⁇ tide having the amino acid sequence
  • X 1 and X2 each represent an optional coupling-faci ⁇ litating amino acid residue and Y represents -NH 9 or -OH.
  • the peptide according to the invention can be produced by suitable known methods for synthesising peptides; for instance, an amino acid can be coupled to the next one to form a peptide bond, either in solution or by so-called solid phase technique.
  • the peptide according to the invention can be synthesised either in amide form or as a free acid, which is indicated by Y representing -NH- or -OH.
  • Another aspect of the invention is directed to mono- clonal antibodies specifically binding to only one epitope of Lys 342 -a. -antitrypsin comprising Lys342.
  • the expression "Lys 342 - . -antitrypsin” is equivalent to the expression
  • the mono ⁇ clonal antibodies should specifically bind to only one epitope of the Z-protein, which epitope comprises the amino acid residue -Lys- which is in position 342 in the Z-protein and which is considered to be the determining amino acid residue distinguishing the Z-protein from the most commonly existing M-protein.
  • Yet another aspect of the invention is directed to a hybridoma cell line producing monoclonal antibodies speci-
  • a further aspect of the invention is directed to a method for producing a hybridoma cell line producing mo ⁇ noclonal antibodies specifically binding to only one epitope of Lys 342-cc. -antitrypsin comprising Lys342. This method consists in that spleen cells derived from a mouse previously immunised with a decapeptide having the amino acid sequence
  • X 1 and X2 each represent an optional coupling-faci ⁇ litating amino acid residue and Y represents - H 2 or -OH, coupled to an inert carrier, are fused with myeloma cells, followed by selection of the hybridoma cells producing said monoclonal antibodies.
  • Spleen cells from other mam ⁇ mals or poultry might be used, but in practice use is made of spleen cells from mouse for producing hybridoma cell lines.
  • the decapeptide coupled to an inert carrier and used for immunising a mouse can be coupled to any inert carrier usable for immunisation purposes.
  • the decapeptide may be coupled to an inert protein, such as bovine serum albumin or hemo- cyanin, or plastic particles.
  • an inert protein such as bovine serum albumin or hemo- cyanin, or plastic particles.
  • the fusion of the spleen cells with myeloma cells can be effected in conventional manner, and a known myeloma cell line can be used.
  • the selection of the hybridoma cell lines producing the desired monoclonal antibodies can be effected in known manner.
  • a further aspect of the invention is directed to a method for in vitro diagnosis of cc, -antitrypsin deficien-
  • 342 cy that is the presence in the blood of Lys -cc -anti ⁇ trypsin, in man, and distinguishing between a heterozygote and a homozygote PiZ gene carrier.
  • This method involves subjecting a blood sample from a human to an immunoassay using monoclonal antibodies specifically binding to only one epitope of Lys 342-cc. -antitrypsin comprising Lys342 as diagnostic antibody.
  • any suitable immuno- assay using a diagnostic antibody can be used for the purposes of the invention, especially suitable methods being radioimmunoassay (RIA), enzyme linked immunosorbent assay (ELISA) and Time-Resolved-Fluorescence.
  • the analysed presence of antigen-antibody complexes confirms the pre- sence of Lys 342-cc.-antitrypsin in the blood sample, that is cc-antitrypsin deficiency in the human from whom the blood sample was taken and analysed and the amount of said complexes revealing if said human is a homozygote or heterozygote PiZ gene carrier. If no antigen-antibody com- plex is detected by the method according to the invention, this means that the blood sample does not contain any Z-protein.
  • the analysed presence of antigen-antibody com ⁇ plexes also indicates whether the blood sample contains homozygous protease inhibitor ZZ or heterozygous protease inhibitor comprising only one Z when the concentration is compared with references.
  • the currently most preferred immunoassay techniques are enzyme linked immunosorbent assay and Time-Resolved-Fluorescence.
  • a final aspect of the invention is directed to an im ⁇ munoassay kit for diagnosing ⁇ .-antitrypsin deficiency in man, which kit comprises a container holding monoclonal antibodies specifically binding to only one epitope of
  • Lys 342-c -antitrypsin comprising Lys342, in an inert medium.
  • the inert medium may be e.g. a phosphate buffer or a physiological saline solution.
  • the immunoassay kit may optionally contain further reagents, diluents etc. in accordance with the immunoassay method to be used. Preparation of peptide coupled to inert carrier A synthetic peptide comprising 11 amino acids was ob ⁇ tained from Peninsula Laboratories, San Fransisco, Cali ⁇ fornia:
  • hemocyanin H-Leu-Thr-Ile-Asp-Lys-Lys-Gly-Thr-Gly-Ala-Cys-OH
  • This peptide was coupled C-terminally to an inert carrier, viz. hemocyanin.
  • the hemocyanin Sigma
  • MBS maleimidobenzoyl-n-hydroxy succinic acid ester
  • Activated hemocyanin was gel-fil- tered on a G-25 column in 10 mM sodium phosphate, pH 7.0.
  • the protein fraction from the gel filtration was mixed with the peptide under agitation for 3 h at room tempera ⁇ ture and was thereafter dialysed against 50 mM Tris-HCl, 0.15 M NaCl, pH 7.5. The resulting coupling product was used for immunisation.
  • the fusion was carried out in polyethylene glycol/dimethyl sulphoxide/water in proportions 45:7:48.
  • the fused cells
  • 5x10 cells of a master clone were injected intrape ⁇ ritoneally in Balb/c mice after an injection of 0.5 ml Pristine (2,6,10,14-tetramethylpentadecane. After 8 days, all ascites fluid was aspirated, and the resulting immu- noglobulins were precipitated with 50% ammonium sulphate. The precipitate was dissolved in water and dialysed against 50 mM Tris-HCl, pH 7.4, and purified on a Mono-Q (Pharmacia) column equilibrated with 20 mM Tris-HCl, pH 8.0. Immunoglobulin fractions, which had been detected with agarose electrophoresis, were pooled and frozen at -70°C. Detection with ELISA technique
  • Monoclonal antibodies according to the invention were labelled in known manner with the earth metal Europium giv ⁇ ing a strong fluorescence of short duration. (See e.g. Hemmila, I. et al, Europium as a Label in Time-Resolved Immunofluorometric Assays, Analytical Biochemistry 137, 335-343 (1984)). Wells in a microtiter plate were incubated at pH 9.6 with a polyclonal antibody against x.-antitrypsin derived from rabbit (Dako No. A 012). To avoid unspecific adsorp ⁇ tion, the remaining surfaces were blocked with 0.1% Tween 20 in phosphate buffer, pH 8.0.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Décapeptide de la séquence d'acides aminés H-X1-Leu-Thr-Ile-Asp-Lys-Lys-Gly-Thr-Gly-Ala-X2-Y, dans laquelle X1 et X2 représentent chacun un reste d'acides aminés facilitant un couplage facultatif, et Y représente NH¿2? ou OH. Sont également décrits des anticorps monoclonaux se liant spécifiquement à uniquement un épitope de Lys?342¿-α¿1?-antitrypsine, par exemple une protéine Z, comprenant Lys?342¿; une lignée cellulaire d'hybridomes produisant lesdits anticorps monoclonaux; ainsi qu'un procédé de préparation de la lignée cellulaire d'hybridomes. Sont églament décrits un procédé de diagnostic in vitro de carence en α¿1?-antitrypsine, par exemple la présence dans le sang de Lys?342¿-α¿1?-antitrypsine, chez l'homme, ainsi qu'un kit d'immunoanalyse permettant ledit diagnostic.
PCT/SE1990/000768 1989-11-28 1990-11-23 Peptide (alpha, at) inhibiteur de trypsine, immunoanalyse, anticorps monoclonal et hybridome WO1991008488A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8904007-5 1989-11-28
SE8904007A SE8904007D0 (sv) 1989-11-28 1989-11-28 Monoklona antikroppar och diagnostiseringsmetod

Publications (1)

Publication Number Publication Date
WO1991008488A1 true WO1991008488A1 (fr) 1991-06-13

Family

ID=20377617

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1990/000768 WO1991008488A1 (fr) 1989-11-28 1990-11-23 Peptide (alpha, at) inhibiteur de trypsine, immunoanalyse, anticorps monoclonal et hybridome

Country Status (5)

Country Link
AU (1) AU7896891A (fr)
IE (1) IE904273A1 (fr)
IL (1) IL96369A0 (fr)
SE (1) SE8904007D0 (fr)
WO (1) WO1991008488A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006019906A1 (fr) * 2004-07-14 2006-02-23 The Regents Of The University Of California Biomarqueur pour detecter de maniere precoce un cancer des ovaires
US7670792B2 (en) 2004-07-14 2010-03-02 The Regents Of The University Of California Biomarkers for early detection of ovarian cancer
US9241976B2 (en) 2011-08-29 2016-01-26 The Regents Of The University Of California Use of HDL-related molecules to treat and prevent proinflammatory conditions
US9488655B2 (en) 2004-07-14 2016-11-08 The Regents Of The University Of California Biomarkers for detection of early- and late-stage endometrial cancer
US9487575B2 (en) 2004-07-14 2016-11-08 The Regents Of The University Of California Compositions and methods for treatment of gynecologic cancers
KR101753447B1 (ko) * 2010-09-24 2017-07-03 그리폴스 테라퓨틱스 인코포레이티드 면역크로마토그래피 장치, 방법 및 키트

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005308A1 (fr) * 1987-12-03 1989-06-15 Gesellschaft Für Biotechnologische Forschung Mbh ( Anticorps monoclonaux et lignees de cellules d'hybridomes utilisees pour les obtenir

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005308A1 (fr) * 1987-12-03 1989-06-15 Gesellschaft Für Biotechnologische Forschung Mbh ( Anticorps monoclonaux et lignees de cellules d'hybridomes utilisees pour les obtenir

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOSCIENCE REPORTS, Vol. 4, 1984, P. HERION et al.: "Monoclonal Antibodies Against Plasma Protease Inhibitors: II. Production and Characterization of 25 Monoclonal Antibodies Against Human Alpha-Anti-Trypsin. Correlation Between Antigenic Structure and Functional Sites", p. 139-147. *
EUR. J. BIOCHEM., Vol. 175, 1988, THOMAS BOELDICKE et al.: "Production of Specific Monoclonal Antibodies Against the Active Sites of Human Pancreatic Secretory Trypsin Inhibitor Variants by in Vitro Immunozation With Synthetic Peptides", p. 259-264. *
JOURNAL OF IMMUNOLOGICAL METHODS, Vol. 107, 1988, BENJAMIN J. DEL TITO et al.: "Detection of Alpha-Antitrypsin from Recombinant Escherichia Coli Lysates Utilizing the Particle Concentration Fluorescence Immunoassay", p. 67-72. *
PROC. NATL. ACAD. SCI. USA, Vol. 81, September 1984, ANDERS WALLMARK et al.: "Monoclonal Antibody Specific for the Mutant PiZAlpha-Antitrypsin and its Application in an Eliza Procedure for Identification of PiZ Gene Carriers", p. 5690-5693. *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006019906A1 (fr) * 2004-07-14 2006-02-23 The Regents Of The University Of California Biomarqueur pour detecter de maniere precoce un cancer des ovaires
US7670792B2 (en) 2004-07-14 2010-03-02 The Regents Of The University Of California Biomarkers for early detection of ovarian cancer
US8323915B2 (en) 2004-07-14 2012-12-04 The Regents Of The University Of California Biomarkers for early detection of ovarian cancer
US9110083B2 (en) 2004-07-14 2015-08-18 The Regents Of The University Of California Biomarkers for early detection of ovarian cancer
US9488655B2 (en) 2004-07-14 2016-11-08 The Regents Of The University Of California Biomarkers for detection of early- and late-stage endometrial cancer
US9487575B2 (en) 2004-07-14 2016-11-08 The Regents Of The University Of California Compositions and methods for treatment of gynecologic cancers
KR101753447B1 (ko) * 2010-09-24 2017-07-03 그리폴스 테라퓨틱스 인코포레이티드 면역크로마토그래피 장치, 방법 및 키트
US9241976B2 (en) 2011-08-29 2016-01-26 The Regents Of The University Of California Use of HDL-related molecules to treat and prevent proinflammatory conditions
US10208103B2 (en) 2011-08-29 2019-02-19 The Regents Of The University Of California Use of HDL-related molecules to treat and prevent proinflammatory conditions

Also Published As

Publication number Publication date
IE904273A1 (en) 1991-06-05
SE8904007D0 (sv) 1989-11-28
AU7896891A (en) 1991-06-26
IL96369A0 (en) 1991-08-16

Similar Documents

Publication Publication Date Title
US7264939B2 (en) Method of detecting native proBNP
Curtiss et al. A novel method for generating region-specific monoclonal antibodies to modified proteins. Application to the identification of human glucosylated low density lipoproteins.
JPWO2003085399A1 (ja) 白血病、前白血病または非白血病性悪性血液疾患の判定方法及び診断薬
EP0410303A1 (fr) Anticorps monoclonal contre l'endothéline-3 ou un de ses précurseurs et son utilisation
ES2367032T3 (es) Anticuerpo monoclonal anti-fibrina soluble humana y procedimiento de ensayo inmunológico usando el anticuerpo.
WO1991008488A1 (fr) Peptide (alpha, at) inhibiteur de trypsine, immunoanalyse, anticorps monoclonal et hybridome
AU715797B2 (en) Methods for determining the presence of brain protein S-100
JP3018110B2 (ja) モノクローナル抗体
KR101338517B1 (ko) 인간 간-카르복실에스터라제 １을 특이적으로 인식하는 단일클론 항체, 상기 항체를 생산하는 하이브리도마 세포주 및 이의 용도
US5051371A (en) Modified β2 -microglobulin
KR960002740B1 (ko) 안티-트롬빈-결합물질 모노클로날 항체, 이를 생산하는 하이브리도마 및 모노클로날 항체를 이용한 트롬빈-결합물질의 정제법 및 측정법
EP0331100A1 (fr) Anticorps anti-endothéline et leur utilisation
US5175113A (en) Modified β2 -microglobulin
AU669490B2 (en) Immunoassay for identifying alcoholics and monitoring alcohol consumption
CA1287801C (fr) Methode de dosage des peptides du collagene humain par immunoessai enzymatique
US4590168A (en) Protein immunoassaying and purification
JP2002107363A (ja) ヒト老化マーカー及びストレスマーカーの検定方法
Nissen et al. Modified β 2-microglobulin
JPH04134097A (ja) ラミニン　フラグメント
JP3610736B2 (ja) Ｈｔｌｖ−ｉｉを特異的に認識するモノクローナル抗体及び該モノクローナル抗体を産生するハイブリドーマ
CA2634638A1 (fr) Dosage biologique et peptides utilises dans celui-ci
JPH0346116B2 (fr)
JPWO2003052417A1 (ja) 細胞外グラニュライシンの検出方法
ÖZTÜRK et al. Production of Monoclonal Antibody Specific for Human Hemoglobin
Nunomura et al. [Original Contribution] Characterization of Mouse Monoclonal Antibodies to Human Protein 4.1 R FERM Domain: Epitope Mapping and Application to FERM Domain Binding to Red Blood Cell Inside-out Vesicles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA FI NO US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA